<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981016</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-URC-2014/21</org_study_id>
    <nct_id>NCT03981016</nct_id>
  </id_info>
  <brief_title>Medical and Surgical Management of Patients With Brain Metastases</brief_title>
  <acronym>CEREMET-LR</acronym>
  <official_title>&quot;In Population&quot; Study of Medical and Surgical Management of Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The integrated cancer research site (SIRIC) of Montpellier proposes to develop a prospective
      and regional Clinical Database Project and regional biological collection (blood and tumor
      samples), which is an expanding data collection designed to contribute to a better understand
      the patient's management with brain metastases including quality of life and
      neuropsychological/cognitive aspects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brain metastases (BM) represent the first cause of tumors of the central nervous system.
      Mortality, morbidity (cognitive disorders, neurological deficits, etc.) and their
      consequences on the quantity and the quality of life are very high. BM represent a real
      public health problem. The incidence is increasing related to the ageing of the population
      and the increase of cancer patient's survival rate. The medico-surgical care has highly
      evolved (neurosurgical progress, radiosurgery, stereotaxic radiotherapy and new chemo and
      targeted therapy).

      Every histological or biological profile requires a specific evaluation, and management.
      Clinical trials are the reference to establish the efficacy and the toxicity of the new
      processes, but usually answer only at a single question and for very selected patients.

      For this reason, the SIRIC Montpellier Cancer proposes to develop a prospective and regional
      Clinical Database Project and regional biological collection (blood and tumor samples), which
      is an expanding data collection designed to contribute to a better understand the patient's
      management with brain metastases including quality of life and neuropsychological/cognitive
      aspects.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Actual">January 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who had a histological study of their brain metastases</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who had a neurosurgery of their brain metastases</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who had a radiotherapy of their brain metastases</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who had a chemotherapy of their brain metastases</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life by using the quality of life questionnaire core (QLQ-C30).</measure>
    <time_frame>24 months</time_frame>
    <description>The EORTC QLQ-C30 uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 (&quot;Not at all&quot;), 2 (&quot;A little&quot;), 3 (&quot;Quite a bit&quot;) and 4 (&quot;Very much&quot;). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.
The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 (&quot;very poor&quot;) to 7 (&quot;excellent&quot;). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by using the quality of life questionnaire - brain neoplasm (BN20)</measure>
    <time_frame>24 months</time_frame>
    <description>The QLQ-BN20 questionnaire contains 20 items organized into four scales; future uncertainty (3 items), visual disorder (3 items); motor dysfunction (3 items); and communication deficit (3 items), and seven single items (headaches, seizures, drowsiness, hair loss, itchy skin, weakness of legs, and bladder control). All items are rated on a four-point Likert-type scale ('1=not at all', 2='a little', '3=quite a bit' and '4=very much'), and are linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and neuropsychological functions by using Montreal Cognitive assessment (MoCA)</measure>
    <time_frame>24 months</time_frame>
    <description>Performance on the MoCA (Range : 0-30; higher score indicates better performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Central Nervous System Tumor</condition>
  <arm_group>
    <arm_group_label>Biological collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the patients include in the study :
blood samples collected at different times : Before surgery and during the post-operative visit and
frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological collection</intervention_name>
    <description>blood samples collected at different times : Before surgery and during the post-operative visit and
frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery</description>
    <arm_group_label>Biological collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult ≥ 18 years

          2. Radiological diagnosis of brain metastases

          3. Patient eligible for neurosurgical exeresis or treatment by radio-surgery

          4. Patient treated in a neurosurgery center of the Languedoc-Roussillon region (whatever
             therapeutic treatment realized on primary tumor)

          5. Present brain metastases not previously treated

          6. Signed informed consent

          7. Patient affiliated to a national insurance system or beneficiary of such a system

        Exclusion Criteria:

          1. Patient with primary brain tumor

          2. Impossibility to be regularly monitored for psychological, family, social, or
             geographical reasons

          3. Subject under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Bauchet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier régional et universitaire de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre médical Oncogard</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique les Franciscaines</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire d'anatomo-pathologie de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre médical Oncodoc Béziers</name>
      <address>
        <city>Béziers</city>
        <state>Hérault</state>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Anatomie et Cytologie Pathologiques de Grabels</name>
      <address>
        <city>Grabels</city>
        <state>Hérault</state>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional et universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Clémentville</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Millénaire</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut régional du cancer</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <state>Pyrénées-orientales</state>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Pierre</name>
      <address>
        <city>Perpignan</city>
        <state>Pyrénées-orientales</state>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012 Sep;14(9):1171-7. doi: 10.1093/neuonc/nos152. Epub 2012 Aug 16.</citation>
    <PMID>22898372</PMID>
  </reference>
  <reference>
    <citation>Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2011 Jan;22(1):1-6, v. doi: 10.1016/j.nec.2010.08.007. Review.</citation>
    <PMID>21109143</PMID>
  </reference>
  <reference>
    <citation>Smedby KE, Brandt L, Bäcklund ML, Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer. 2009 Dec 1;101(11):1919-24. doi: 10.1038/sj.bjc.6605373. Epub 2009 Oct 13.</citation>
    <PMID>19826419</PMID>
  </reference>
  <reference>
    <citation>Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011 Jan 10;29(2):134-41. doi: 10.1200/JCO.2010.30.1655. Epub 2010 Nov 1.</citation>
    <PMID>21041710</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nervous</keyword>
  <keyword>Central</keyword>
  <keyword>Tumor</keyword>
  <keyword>System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

